NewslettersCell Therapy NewsUncategorizedHemophagocytic Lymphohistiocytosis-Like Toxicity (carHLH) after CD19-Specific CAR T-cell TherapyBy Justin.choi - July 16, 2021011Researchers reported the development of carHLH in 14·8% of paediatric patients and young adults treated with CD19-specific CAR T-cell therapy with carHLH, occurring most commonly in those with high disease burden.[British Journal of Haematology] 6445218 {6445218:KL35AHJ7} apa 50 1 164686 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Abstract